BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29229829)

  • 21. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
    Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
    Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
    Hammer S; Hagemann UB; Zitzmann-Kolbe S; Larsen A; Ellingsen C; Geraudie S; Grant D; Indrevoll B; Smeets R; von Ahsen O; Kristian A; Lejeune P; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS; Mumberg D
    Clin Cancer Res; 2020 Apr; 26(8):1985-1996. PubMed ID: 31831560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
    Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
    Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
    Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.
    Cao KY; Xu L; Zhang DM; Zhang XM; Zhang T; He X; Wang Z; Feng FS; Qiu SP; Shen GX
    Int J Oncol; 2012 Jun; 40(6):1977-85. PubMed ID: 22322627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
    Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
    Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
    Peng ZH; Sima M; Salama ME; Kopečková P; Kopeček J
    J Drug Target; 2013 Dec; 21(10):968-80. PubMed ID: 24160903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP; Minn I; Vaidyanathan G; Hobbs RF; Josefsson A; Shen C; Brummet M; Chen Y; Choi J; Koumarianou E; Baidoo K; Brechbiel MW; Mease RC; Sgouros G; Zalutsky MR; Pomper MG
    J Nucl Med; 2016 Oct; 57(10):1569-1575. PubMed ID: 27230930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-PET for Prostate Cancer: Preclinical investigation using
    Umbricht CA; Köster U; Bernhardt P; Gracheva N; Johnston K; Schibli R; van der Meulen NP; Müller C
    Sci Rep; 2019 Nov; 9(1):17800. PubMed ID: 31780798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer.
    Deegen P; Thomas O; Nolan-Stevaux O; Li S; Wahl J; Bogner P; Aeffner F; Friedrich M; Liao MZ; Matthes K; Rau D; Rattel B; Raum T; Kufer P; Coxon A; Bailis JM
    Clin Cancer Res; 2021 May; 27(10):2928-2937. PubMed ID: 33504551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.
    Shen CJ; Minn I; Hobbs RF; Chen Y; Josefsson A; Brummet M; Banerjee SR; Brayton CF; Mease RC; Pomper MG; Kiess AP
    Theranostics; 2020; 10(7):2888-2896. PubMed ID: 32194842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
    Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
    Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.
    Ngen EJ; Chen Y; Azad BB; Boinapally S; Jacob D; Lisok A; Shen C; Hossain MS; Jin J; Bhujwalla ZM; Pomper MG; Banerjee SR
    Nanotheranostics; 2021; 5(2):182-196. PubMed ID: 33564617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
    Kranzbühler B; Sousa R; Prause L; Burger IA; Rupp NJ; Sulser T; Salemi S; Eberli D
    Cancer Rep (Hoboken); 2021 Dec; 4(6):e1418. PubMed ID: 34008909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
    DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
    Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.
    Li X; Liu YH; Zhang YP; Zhang S; Pu X; Gardner TA; Jeng MH; Kao C
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5463-73. PubMed ID: 17875776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
    Gao Y; Li Y; Li Y; Yuan L; Zhou Y; Li J; Zhao L; Zhang C; Li X; Liu Y
    Nanoscale; 2015 Jan; 7(2):597-612. PubMed ID: 25419788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
    Kularatne SA; Venkatesh C; Santhapuram HK; Wang K; Vaitilingam B; Henne WA; Low PS
    J Med Chem; 2010 Nov; 53(21):7767-77. PubMed ID: 20936874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.